Gatralimab

格曲利单抗

Report date: 2023/05/17 20:00:39

Base Information

Drug NameGatralimab
Drug Alias NameGLD-52GZ-402668
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCAMPATH-1 antigen modulatorsImmunosuppressants
TargetsCAMPATH-1 antigen
Therapy Area/IndicationsMultiple Sclerosis, Chronic Progressive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenzyme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiGenzyme Corp
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis, Chronic Progressive

Other Information

ATC CodeN/A
Related LinksN/A